Back
TScan Therapeutics, Inc. 10K Form
Sell
11
TCRX
TScan Therapeutics, Inc.
Last Price:
$1.02
Seasonality Move:
-6.74%
7 Day Trial
ALL ACCESS PASS
$
7
Key Filings
10K form not available
Receive TCRX News And Ratings
See the #1 stock for the next 7 days that we like better than TCRX
TCRX Financial Statistics
Sales & Book Value
| Annual Sales: | $10.3M |
|---|---|
| Cash Flow: | $-32.2M |
| Price / Cash Flow: | 0 |
| Annual Sales: | $2.16 |
| Price / Book: | 0.46 |
Profitability
| EPS (TTM): | -0.99990 |
|---|---|
| Net Income (TTM): | $-129.8M |
| Gross Margin: | $7.5M |
| Return on Equity: | -72.49% |
| Return on Assets: | -43.45% |
TScan Therapeutics, Inc. Earnings Forecast
Key TScan Therapeutics, Inc. Financial Ratios
-
The Gross Profit Margin over the past 7 years for TCRX is 72.24%.
-
The Selling, General & Administrative Expenses for TCRX have been equal to 309.81% of Gross Profit Margin.
-
The Research & Development expenses have been 1,084.16% of Revenue.
-
The Net Earning history of TCRX is -1,256.81% of Total Revenues.
-
Per Share Earnings over the last 7 years have been positive in 4 years.
TScan Therapeutics, Inc. Stock Price Chart
Industry, Sector and Symbol
| Stock Exchange: | NASDAQ |
|---|---|
| Industry: | Biotechnology |
| Sector: | Health Care |
| Current Symbol: | TCRX |
| Website: | tscan.com |
Debt
| Debt-to-Equity Ratio: | 0.76 |
|---|---|
| Current Ratio: | 8.41 |
| Quick Ratio: | 8.15 |
Price-to-Earnings
| Trailing P/E Ratio: | 0 |
|---|---|
| Forward P/E Ratio: | 0 |
TCRX Technical Analysis vs Fundamental Analysis
Sell
11
TScan Therapeutics, Inc. (TCRX)
is a Sell
Is TScan Therapeutics, Inc. a Buy or a Sell?
-
TScan Therapeutics, Inc. stock is rated a SellThe current TScan Therapeutics, Inc. [TCRX] share price is $1.01. The Score for TCRX is 11, which is 78% below its historic median score of 50, and infers higher risk than normal.